Amgen sBLA for Enbrel accepted by the FDA for review
Amgen has announced that its supplemental Biologics License Application (sBLA) for the extended use of Enbrel (etanercept) in the treatment of chronic severe plaque psoriasis in pediatric patients has been accepted for review by the U.S. Food and Drug Administration (FDA). Read More »